Clinical Trial

Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausal Women

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated January 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
This randomized, double-blind, placebo-controlled clinical trial aims to investigate the effect of flaxseed-derived phytoestrogen supplementation on gene expression of Anti-Müllerian Hormone (AMH) and its receptor (AMHR2), as well as the experience and severity of premenstrual syndrome (PMS), among perimenopausal women aged 40-55 years in Jordan. Participants will receive either flaxseed phytoestrogen extract (secoisolariciresinol diglucoside, SDG) or placebo for 12 weeks. Changes in gene expression and PMS severity will be assessed at baseline and post-intervention to explore the potential role of phytoestrogens in modulating ovarian aging and menstrual-related symptoms.
Trial Details
NCT Number NCT07310485
Lead Sponsor University of Jordan
Conditions Apparently Healthy and Not Receiving Hormonal Therapy
Enrollment 70 participants
Start Date 2025-11-01
Primary Completion 2026-01-02 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-30